Skip to main content

Table 2 Toxicity

From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

  Grade
  0 1 2 3
No. of patients (%)     
Hematologic     
Neutropenia 40 (88.9) 3 (6.7) 2 (4.4)  
Anemia 35 (77.8) 5 (11.1) 5 (11.1)  
Non hematologic     
Nausea/vomiting 29 (64.4) 13 (28.9) 3 (6.7)  
Diarrhea 23 (51.1) 17 (37.8) 5 (11.1)  
Stomatitis 40 (88.9) 4 (8.9) 1 (2.2)  
Hand and foot syndrome 17 (37.8) 12 (26.7) 11 (24.4) 5 (11.1)
Onycholysis 43 (95.6) 2 (4.4)   
Hypertension 27 (60.0) 16 (35.6) 2 (4.4)  
Proteinuria 20 (44.4) 13 (28.9) 7 (15.6) 2 (4.4)
Hemorrhage 42 (93.7) 3 (6.7)   
Thrombosis 43 (95.6) 2 (4.4)   
Cardiac 44 (97.8) 1 (2.2)   
Fever 34 (75.5) 11 (24.4)   
Asthenia 27 (60.0) 15 (33.3) 3 (6.7)